Carbonic anhydrase inhibitors and activators and their

Expert Opinion on Therapeutic Patents 16, 1627-1664

DOI: 10.1517/13543776.16.12.1627

Citation Report

#	Article	IF	Citations
1	Therapeutic applications of the carbonic anhydrase inhibitors. Therapy: Open Access in Clinical Medicine, 2007, 4, 355-378.	0.2	29
2	Carbonic anhydrase IX inhibitors: fluorescent sulfonamides as therapeutic and diagnostic agents. Expert Opinion on Therapeutic Patents, 2007, 17, 1393-1396.	2.4	3
3	Structural Analysis of Charge Discrimination in the Binding of Inhibitors to Human Carbonic Anhydrases I and II. Journal of the American Chemical Society, 2007, 129, 5528-5537.	6.6	62
4	Homology Modeling and Receptor-Based 3D-QSAR Study of Carbonic Anhydrase IX. Journal of Chemical Information and Modeling, 2007, 47, 2253-2262.	2.5	26
5	Saccharin Inhibits Carbonic Anhydrases: Possible Explanation for its Unpleasant Metallic Aftertaste. Angewandte Chemie - International Edition, 2007, 46, 7697-7699.	7.2	168
6	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. Bioorganic and Medicinal Chemistry, 2007, 15, 2298-2311.	1.4	44
7	Carbonic anhydrases as targets for medicinal chemistry. Bioorganic and Medicinal Chemistry, 2007, 15, 4336-4350.	1.4	521
8	QSAR studies on the activation of the human carbonic anhydrase cytosolic isoforms I and II and secretory isozyme VI with amino acids and amines. Bioorganic and Medicinal Chemistry, 2007, 15, 6501-6509.	1.4	4
9	Carbonic anhydrase inhibitors: Cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorganic and Medicinal Chemistry, 2007, 15, 7229-7236.	1.4	100
10	Carbonic anhydrase activators: An activation study of the human mitochondrial isoforms VA and VB with amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1336-1340.	1.0	44
11	Anti-mycobacterial activity of a bis-sulfonamide. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1355-1357.	1.0	32
12	Carbonic anhydrase inhibitors: Binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1726-1731.	1.0	38
13	Carbonic anhydrase inhibitors: Inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1538-1543.	1.0	29
14	Carbonic anhydrase inhibitors. Inhibition of transmembrane isozymes XII (cancer-associated) and XIV with anions. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1532-1537.	1.0	35
15	Carbonic anhydrase inhibitors: The X-ray crystal structure of the adduct of N-hydroxysulfamide with isozyme II explains why this new zinc binding function is effective in the design of potent inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2795-2801.	1.0	15
16	Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranose–thioureido tails. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2685-2691.	1.0	48
17	Carbonic anhydrase inhibitors: The $\hat{1}^2$ -carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3585-3594.	1.0	157
18	Carbonic anhydrase activators: Activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4107-4112.	1.0	48

#	Article	IF	CITATIONS
19	Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: Kinetic and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4866-4872.	1.0	37
20	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I and II, and extracellular isoforms IV, IX, and XII with sulfamides incorporating sugar moieties. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5086-5090.	1.0	41
21	Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2210-2215.	1.0	48
22	Carbonic anhydrase inhibitors: Inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides—Solution and crystallographic studies. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4201-4207.	1.0	47
23	Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer and Metastasis Reviews, 2007, 26, 299-310.	2.7	470
24	Carbonic anhydrase IX: A new druggable target for the design of antitumor agents. Medicinal Research Reviews, 2008, 28, 445-463.	5.0	210
25	Carbonic anhydrase activators: Activation of the human tumor-associated isozymes IX and XII with amino acids and amines. Bioorganic and Medicinal Chemistry, 2008, 16, 3530-3536.	1.4	45
26	Carbonic anhydrase inhibitors: Inhibition of mammalian isoforms I–XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorganic and Medicinal Chemistry, 2008, 16, 7424-7428.	1.4	120
27	In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorganic and Medicinal Chemistry, 2008, 16, 9101-9105.	1.4	160
28	Carbonic anhydrase inhibitors. Interaction of 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide with 12 mammalian isoforms: Kinetic and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 152-158.	1.0	49
29	Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: Kinetic and X-ray crystallographic studies. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 999-1005.	1.0	22
30	Carbonic anhydrase inhibitors: Interactions of phenols with the 12 catalytically active mammalian isoforms (CA l–XIV). Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1583-1587.	1.0	186
31	Carbonic anhydrase inhibitors: The very weak inhibitors dithiothreitol, \hat{l}^2 -mercaptoethanol, tris(carboxyethyl)phosphine and threitol interfere with the binding of sulfonamides to isozymes II and IX. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1898-1903.	1.0	7
32	Carbonic anhydrase inhibitors: Thioxolone versus sulfonamides for obtaining isozyme-selective inhibitors?. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3938-3941.	1.0	37
33	Carbonic anhydrase activators: Activation of the human cytosolic isozyme III and membrane-associated isoform IV with amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4303-4307.	1.0	30
34	Carbonic anhydrase activators: Activation of the archaeal \hat{l}^2 -class (Cab) and \hat{l}^3 -class (Cam) carbonic anhydrases with amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6194-6198.	1.0	36
35	Kinetic and mechanistic studies of the hydrolysis of sulfamate esters: a non-elimination decomposition route. Tetrahedron Letters, 2008, 49, 1049-1052.	0.7	11
36	Carbonic anhydrase inhibitors: The X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2669-2674.	1.0	35

#	ARTICLE	IF	CITATIONS
37	Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3593-3596.	1.0	63
38	Inhibition of Carbonic Anhydrases with Glycosyltriazole Benzene Sulfonamides. Journal of Medicinal Chemistry, 2008, 51, 1945-1953.	2.9	77
39	Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Reviews Drug Discovery, 2008, 7, 168-181.	21.5	2,702
40	Cancer-associated, hypoxia-inducible carbonic anhydrase IX facilitates CO2diffusion. BJU International, 2008, 101, 22-24.	1.3	61
41	Dual Inhibitors of Matrix Metalloproteinases and Carbonic Anhydrases: Iminodiacetyl-Based Hydroxamateâ^'Benzenesulfonamide Conjugates. Journal of Medicinal Chemistry, 2008, 51, 7968-7979.	2.9	52
42	Carbonic Anhydrase as a Model for Biophysical and Physical-Organic Studies of Proteins and Proteinâ "Ligand Binding. Chemical Reviews, 2008, 108, 946-1051.	23.0	638
43	In vitro inhibition of cytosolic carbonic anhydrases I and II by some new dihydroxycoumarin compounds. Journal of Enzyme Inhibition and Medicinal Chemistry, 2008, 23, 32-36.	2.5	10
44	The Alpha-Carbonic Anhydrase from the Malaria Parasite and its Inhibition. Current Pharmaceutical Design, 2008, 14, 631-640.	0.9	74
46	Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 499-505.	2.5	25
47	Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Medicinal Research Reviews, 2009, 29, 419-435.	5.0	104
48	Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms l–XIV. Bioorganic and Medicinal Chemistry, 2009, 17, 5791-5795.	1.4	110
49	Screening and docking studies of natural phenolic inhibitors of carbonic anhydrase II. Science in China Series B: Chemistry, 2009, 52, 332-337.	0.8	9
50	Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins: Structure, Function and Bioinformatics, 2009, 74, 164-175.	1.5	97
51	Carbonic anhydrase activators. Activation of the membrane-associated isoform XV with amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3430-3433.	1.0	11
52	Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6014-6017.	1.0	44
53	Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorganic and Medicinal Chemistry, 2009, 17, 3207-3211.	1.4	207
57	Selectivity Issues in the Design of CA Inhibitors. , 0, , 399-413.		0
58	Carbonic anhydrase activators. The first activation study of a coral secretory isoform with amino acids and amines. Bioorganic and Medicinal Chemistry, 2010, 18, 2300-2303.	1.4	28

#	ARTICLE	IF	CITATIONS
59	NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II. Bioorganic and Medicinal Chemistry, 2010, 18, 3559-3563.	1.4	59
60	Indapamide-like benzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, and XIII. Bioorganic and Medicinal Chemistry, 2010, 18, 7357-7364.	1.4	35
61	The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis. BMC Cancer, 2010, 10, 148.	1,1	71
62	Bidentate Zinc Chelators for αâ€Carbonic Anhydrases that Produce a Trigonal Bipyramidal Coordination Geometry. ChemMedChem, 2010, 5, 1609-1615.	1.6	27
63	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I–XIV with a series of natural product polyphenols and phenolic acids. Bioorganic and Medicinal Chemistry, 2010, 18, 2159-2164.	1.4	204
64	A novel and one-pot synthesis of new 1-tosyl pyrrol-2-one derivatives and analysis of carbonic anhydrase inhibitory potencies. Bioorganic and Medicinal Chemistry, 2010, 18, 4468-4474.	1.4	68
65	Carbonic anhydrase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3467-3474.	1.0	579
66	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I–XV. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5050-5053.	1.0	151
67	Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of \hat{l}_{\pm} - but not of \hat{l}^{2} -, \hat{l}^{3} - and \hat{l}_{\pm} - carbonic anhydrases. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6208-6212.	1.0	49
68	Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII. Current Medicinal Chemistry, 2010, 17, 1516-1526.	1.2	100
69	Cloning, Characterization, and Inhibition Studies of a \hat{l}^2 -Carbonic Anhydrase from $\langle i \rangle$ Brucella suis $\langle i \rangle$. Journal of Medicinal Chemistry, 2010, 53, 2277-2285.	2.9	104
70	Carbonic anhydrase inhibitors: Gd(iii) complexes of DOTA- and TETA-sulfonamide conjugates targeting the tumor associated carbonic anhydrase isozymes IX and XII. New Journal of Chemistry, 2010, 34, 2139.	1.4	5
71	Characterization and inhibition studies of an \hat{l} ±-carbonic anhydrase from the endangered sturgeon species <i>Acipenser gueldenstaedti</i> . Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, 26, 895-900.	2.5	51
72	Interfering with pH regulation in tumours as a therapeutic strategy. Nature Reviews Drug Discovery, 2011, 10, 767-777.	21.5	1,340
73	Malaria parasite carbonic anhydrase: inhibition of aromatic/heterocyclic sulfonamides and its therapeutic potential. Asian Pacific Journal of Tropical Biomedicine, 2011, 1, 233-242.	0.5	35
74	<i>In Vitro Inhibition of Human Carbonic Anhydrase I and II Isozymes with Natural Phenolic Compounds. Chemical Biology and Drug Design, 2011, 77, 494-499.</i>	1.5	170
75	Honey, polen, and propolis extracts show potent inhibitory activity against the zinc metalloenzyme carbonic anhydrase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, 26, 440-444.	2.5	38
76	Inhibition studies of the \hat{l}^2 -carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates. Bioorganic and Medicinal Chemistry, 2011, 19, 5023-5030.	1.4	56

#	Article	IF	CITATIONS
77	Inhibition studies with anions and small molecules of two novel \hat{l}^2 -carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3591-3595.	1.0	70
78	In vitro inhibition of \hat{l} ±-carbonic anhydrase isozymes by some phenolic compounds. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4259-4262.	1.0	170
79	Theoretical improvement of the specific inhibitor of human carbonic anhydrase VII. Computational Biology and Chemistry, 2011, 35, 50-56.	1.1	9
80	Synthesis and characterization of a novel amino salicylato salt and its Cu(II) complex and their inhibition studies on carbonic anhydrase isoenzymes. Polyhedron, 2011, 30, 535-541.	1.0	17
81	Carbonic anhydrase I and II inhibition with natural products: caffeine and piperine. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 97-100.	2.5	8
82	3D-QSAR Study of Some Heterocyclic Sulfonamide Analogs as hCAII Inhibitors. Letters in Drug Design and Discovery, 2012, 9, 581-586.	0.4	1
83	Chromone containing sulfonamides as potent carbonic anhydrase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 744-747.	2.5	42
84	The first activation study of a bacterial carbonic anhydrase (CA). The thermostable α-CA from Sulfurihydrogenibium yellowstonense YO3AOP1 is highly activated by amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6324-6327.	1.0	73
85	Inhibition of human carbonic anhydrase isozymes I, II and VI with a series of bisphenol, methoxy and bromophenol compounds. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 467-475.	2.5	39
86	Evaluation of in vitro effects of some analgesic drugs on erythrocyte and recombinant carbonic anhydrase I and II. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 37-42.	2.5	16
87	Inhibition of carbonic anhydrase IX as a novel anticancer mechanism. World Journal of Clinical Oncology, 2012, 3, 98.	0.9	79
88	Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?. Chemical Reviews, 2012, 112, 4421-4468.	23.0	1,056
89	Update on carbonic anhydrase inhibitors: a patent review (2008 – 2011). Expert Opinion on Therapeutic Patents, 2012, 22, 903-915.	2.4	102
90	Design of [(2-pyrimidinylthio)acetyl]benzenesulfonamides as inhibitors of human carbonic anhydrases. European Journal of Medicinal Chemistry, 2012, 51, 259-270.	2.6	33
91	Synthesis and carbonic anhydrase inhibitory properties of novel coumarin derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 299-304.	2.5	26
92	Analysis of saponins and phenolic compounds as inhibitors of $\hat{l}\pm$ -carbonic anhydrase isoenzymes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 412-417.	2.5	51
93	Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship. European Journal of Medicinal Chemistry, 2013, 62, 597-604.	2.6	6
94	Insights towards sulfonamide drug specificity in $\hat{l}\pm$ -carbonic anhydrases. Bioorganic and Medicinal Chemistry, 2013, 21, 1526-1533.	1.4	102

#	ARTICLE	IF	Citations
95	Glycosidic carbonic anhydrase IX inhibitors: A sweet approach against cancer. Bioorganic and Medicinal Chemistry, 2013, 21, 1419-1426.	1.4	58
96	Heavy metal ion inhibition studies of human, sheep and fish \hat{l}_{\pm} -carbonic anhydrases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 278-282.	2.5	38
97	Structural annotation of human carbonic anhydrases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 267-277.	2.5	189
98	Selective carbonic anhydrase IX inhibitors based on coumarin scaffold as promising antimetastatic agents: WO2012070024. Expert Opinion on Therapeutic Patents, 2013, 23, 751-756.	2.4	16
99	The extremo-α-carbonic anhydrase (CA) from Sulfurihydrogenibium azorense, the fastest CA known, is highly activated by amino acids and amines. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1087-1090.	1.0	55
100	Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005 – 2013). Expert Opinion on Therapeutic Patents, 2013, 23, 681-691.	2.4	252
101	Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 1511-1515.	1.4	12
102	Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review . Expert Opinion on Therapeutic Patents, 2013, 23, 717-724.	2.4	172
103	Medicinal significance of benzothiazole scaffold: an insight view. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 240-266.	2.5	188
104	Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2013, 23, 705-716.	2.4	273
105	Benzenesulfonamides with pyrimidine moiety as inhibitors of human carbonic anhydrases I, II, VI, VII, XII, and XIII. Bioorganic and Medicinal Chemistry, 2013, 21, 6937-6947.	1.4	40
106	Investigation of heavy metal effects on immobilized paraoxanase by glutaraldehyde. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 440-446.	2.5	3
107	Inhibition studies of new ureido-substituted sulfonamides incorporating a GABA moiety against human carbonic anhydrase isoforms l–XIV. Bioorganic and Medicinal Chemistry, 2014, 22, 6768-6775.	1.4	23
108	New coumarin derivatives as carbonic anhydrase inhibitors. Artificial Cells, Nanomedicine and Biotechnology, 2014, 42, 192-198.	1.9	13
109	Sulfamic Acid and Its N- and O-Substituted Derivatives. Chemical Reviews, 2014, 114, 2507-2586.	23.0	92
110	Sulfamates of methyl triterpenoates are effective and competitive inhibitors of carbonic anhydrase II. European Journal of Medicinal Chemistry, 2014, 86, 95-102.	2.6	20
111	Synthesis and Cytotoxic Activity of Pentacyclic Triterpenoid Sulfamates. Archiv Der Pharmazie, 2015, 348, 46-54.	2.1	20
112	The impact of hydroquinone on acetylcholine esterase and certain human carbonic anhydrase isoenzymes (hCA I, II, IX, and XII). Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 941-946.	2.5	96

#	Article	IF	CITATIONS
113	Investigation of arenesulfonyl-2-imidazolidinones as potent carbonic anhydrase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 81-84.	2.5	40
114	Synthesis and evaluation of new phthalazine substituted \hat{l}^2 -lactam derivatives as carbonic anhydrase inhibitors. Russian Journal of Bioorganic Chemistry, 2015, 41, 414-420.	0.3	23
115	Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Review of Neurotherapeutics, 2015, 15, 851-856.	1.4	128
116	Inhibition of mammalian carbonic anhydrase isoforms l–XIV with a series of phenolic acid esters. Bioorganic and Medicinal Chemistry, 2015, 23, 7181-7188.	1.4	26
117	Carbonic anhydrase inhibitors: guaiacol and catechol derivatives effectively inhibit certain human carbonic anhydrase isoenzymes (hCA I, II, IX and XII). Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 586-591.	2.5	121
118	Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer. Diagnostic Pathology, 2016, 11, 45.	0.9	54
119	Ultrasound accelerated sulfonylation of amines by <i>p</i> i>-acetamidobenzenesulfonyl chloride using Mg–Al hydrotalcite as an efficient green base catalyst. Journal of Sulfur Chemistry, 2016, 37, 515-528.	1.0	2
120	Synthesis of 4â€[2â€(3,4â€dimethoxybenzyl)cyclopentyl]â€1,2â€dimethoxybenzene Derivatives and Evaluations Their Carbonic Anhydrase Isoenzymes Inhibitory Effects. Chemical Biology and Drug Design, 2016, 87, 594-607.	of 1.5	46
121	Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 423-431.	1.5	86
122	Characterization and inhibition studies of carbonic anhydrase from gill of Russian Sturgeon Fish (<i>Acipenser gueldenstaedtii</i>). Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1662-1665.	2.5	6
123	Activation modelling of \hat{l}^2 - and \hat{l}^3 -class of carbonic anhydrase with amines and amino acids: Proton transfer process within the active site from thermodynamic point of view. Computational and Theoretical Chemistry, 2017, 1109, 42-57.	1.1	5
124	Synthesis and carbonic anhydrase inhibitory properties of new spiroindoline-substituted sulphonamide compounds. Archives of Physiology and Biochemistry, 2017, 123, 306-312.	1.0	5
125	<i>N</i> -Acylbenzenesulfonamide Dihydro-1,3,4-oxadiazole Hybrids: Seeking Selectivity toward Carbonic Anhydrase Isoforms. ACS Medicinal Chemistry Letters, 2017, 8, 792-796.	1.3	27
126	Novel eugenol derivatives: Potent acetylcholinesterase and carbonic anhydrase inhibitors. International Journal of Biological Macromolecules, 2017, 94, 845-851.	3.6	100
127	Development of selective QSAR models and molecular docking study for inhibitory activity of sulfonamide derivatives against carbonic anhydrase isoforms II and IX. Journal of Molecular Structure, 2018, 1163, 270-279.	1.8	11
128	The determination of the carbonic anhydrases activators <i>in vitro</i> effect of mixed donor crown ethers. Journal of Biochemical and Molecular Toxicology, 2018, 32, e22032.	1.4	8
129	Synthesis, anti-cancer screening and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibition activity of novel piperidinyl sulfamides. European Journal of Pharmaceutical Sciences, 2018, 111, 337-348.	1.9	13
130	New Strategy for in Vitro Determination of Carbonic Anhydrase Activity from Analysis of Oxygen-18 Isotopes of CO ₂ . Analytical Chemistry, 2018, 90, 1384-1387.	3.2	3

#	Article	IF	CITATIONS
131	Enzymatic Nanocomposites with Radio Frequency Field-Modulated Activity. ACS Biomaterials Science and Engineering, 2018, 4, 3962-3967.	2.6	18
132	Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opinion on Therapeutic Patents, 2018, 28, 713-721.	2.4	97
133	<i>meta</i> yanobenzyl substituted benzimidazolium salts: Synthesis, characterization, crystal structure and carbonic anhydrase, αâ€glycosidase, butyrylcholinesterase, and acetylcholinesterase inhibitory properties. Archiv Der Pharmazie, 2018, 351, e1800029.	2.1	62
134	Carbonic anhydrase inhibitors as diuretics. , 2019, , 287-309.		O
135	A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitors. European Journal of Medicinal Chemistry, 2019, 181, 111565.	2.6	23
136	Synthesis and biological evaluation of some new mono Mannich bases with piperazines as possible anticancer agents and carbonic anhydrase inhibitors. Bioorganic Chemistry, 2019, 90, 103095.	2.0	53
137	Fast Microsecond Dynamics of the Protein–Water Network in the Active Site of Human Carbonic Anhydrase II Studied by Solid-State NMR Spectroscopy. Journal of the American Chemical Society, 2019, 141, 19276-19288.	6.6	46
138	DFT-based QSAR modelling of selectivity and inhibitory activity of coumarins and sulfocoumarins against tumor-associated carbonic anhydrase isoform IX. Computational Biology and Chemistry, 2019, 80, 307-313.	1.1	8
139	Activation and inhibition effects of some natural products on human cytosolic CAI and CAII. Medicinal Chemistry Research, 2019, 28, 711-722.	1.1	16
140	A selectivity study of benzenesulfonamide derivatives on human carbonic anhydrase II/IX by 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation. Computational Biology and Chemistry, 2019, 80, 234-243.	1.1	16
141	Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents. Bioorganic Chemistry, 2020, 95, 103557.	2.0	40
142	Design, synthesis and biological evaluation of novel carbohydrate-based sulfonamide derivatives as antitumor agents. Bioorganic Chemistry, 2020, 104, 104237.	2.0	15
143	Review of the Synthesis and Anticancer Properties of Pyrazolo[4,3-e][1,2,4]triazine Derivatives. Molecules, 2020, 25, 3948.	1.7	20
144	Study of glycation process of human carbonic anhydrase II as well as investigation concerning inhibitory influence of 3-beta-hydroxybutyrate on it. International Journal of Biological Macromolecules, 2020, 149, 443-449.	3.6	9
145	From Homology Modeling to the Hit Identification and Drug Repurposing: A Structure-Based Approach in the Discovery of Novel Potential Anti-Obesity Compounds. Methods in Molecular Biology, 2021, 2266, 263-277.	0.4	3
146	Sulfonamide Based \hat{l}^2 -Carbonic Anhydrase Inhibitors: 2D QSAR Study. ISRN Medicinal Chemistry, 2013, 2013, 1-8.	0.6	2
147	Coumarin sulfonamide derivatives: An emerging class of therapeutic agents. Heterocyclic Communications, 2020, 26, 46-59.	0.6	26
148	In vitro inhibition of purified human carbonic anhydrase I and II by novel fluorene derivatives. Macedonian Journal of Chemistry and Chemical Engineering, 2014, 33, 199.	0.2	2

#	Article	IF	CITATIONS
149	DFT-Based QSAR Modelling of Inhibitory Activity of Coumarins and Sulfocoumarins on Carbonic Anhydrase (CA) Isoforms (CA I and CA II). Current Computer-Aided Drug Design, 2019, 15, 243-251.	0.8	1
150	Carbonic Anhydrase I and II Inhibition with Natural Products: Leucas cephalotes. Pharmacognosy Communications, 2011, 1, 41-46.	0.4	2
151	Synthesis and Evaluation of New Phthalazine Substituted β-Lactam Derivatives as Carbonic Anhydrase Inhibitors. BioorganiÄeskaâ Himiâ, 2015, 41, 468-474.	0.2	3
152	Coumarin or benzoxazinone bearing benzimidazolium and bis(benzimidazolium) salts; involvement in transfer hydrogenation of acetophenone derivatives and hCA inhibition. Mediterranean Journal of Chemistry, 2015, 4, 252-260.	0.3	0
153	Çuha Çiçeği (Oenothera biennis) ve Tatlı Badem (Prunus dulcis Mill) Yağlarının Anti-enzim Aktivitelerir Araştırılması. European Journal of Science and Technology, 0, , 583-590.	nin 0.5	1
154	Utilization of transition metal fluoride-based solid support catalysts for the synthesis of sulfonamides: carbonic anhydrase inhibitory activity and in silico study. RSC Advances, 2022, 12, 3165-3179.	1.7	2
155	Recent advances in the design and synthesis of small molecule carbonic anhydrase IX inhibitors. Current Topics in Medicinal Chemistry, 2022, 22, .	1.0	1
157	A novel series of thiosemicarbazone hybrid scaffolds: Design, synthesis, DFT studies, metabolic enzyme inhibition properties, and molecular docking calculations. Journal of Molecular Structure, 2023, 1280, 135077.	1.8	16